274 related articles for article (PubMed ID: 28662034)
1. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
3. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
5. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
6. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
7. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
9. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.
Ramos JM; Clavijo A; Moral L; Gavilan C; Salvador T; González de Dios J
Paediatr Int Child Health; 2018 Aug; 38(3):203-208. PubMed ID: 29790825
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
Lyra MR; Oliveira LFA; Schubach AO; Sampaio RNR; Rodrigues BC; Hueb M; Cota G; Silva RE; Francesconi F; Pompilio MA; França AO; Amato VS; Souza RM; Oliveira RVC; Valete CM; Pimentel MIF
Clin Infect Dis; 2023 Aug; 77(4):574-582. PubMed ID: 37100061
[TBL] [Abstract][Full Text] [Related]
14. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
[TBL] [Abstract][Full Text] [Related]
15. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda.
Mueller Y; Nguimfack A; Cavailler P; Couffignal S; Rwakimari JB; Loutan L; Chappuis F
Ann Trop Med Parasitol; 2008 Jan; 102(1):11-9. PubMed ID: 18186974
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Mediterranean visceral leishmaniasis.
Gradoni L; Bryceson A; Desjeux P
Bull World Health Organ; 1995; 73(2):191-7. PubMed ID: 7743590
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
Khalil EA; Weldegebreal T; Younis BM; Omollo R; Musa AM; Hailu W; Abuzaid AA; Dorlo TP; Hurissa Z; Yifru S; Haleke W; Smith PG; Ellis S; Balasegaram M; EL-Hassan AM; Schoone GJ; Wasunna M; Kimutai R; Edwards T; Hailu A
PLoS Negl Trop Dis; 2014; 8(1):e2613. PubMed ID: 24454970
[TBL] [Abstract][Full Text] [Related]
19. The direct costs of treating human visceral leishmaniasis in Brazil.
Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
[TBL] [Abstract][Full Text] [Related]
20. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]